Quick Answer
Cardiff Oncology, Inc. reported Stockholders Equity of $45.39 million for fiscal year 2025.
Cardiff Oncology, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $45.39M | -45.3% |
| 2024 | $82.95M | +18.9% |
| 2023 | $69.74M | -34.4% |
| 2022 | $106.34M | -24.3% |
| 2021 | $140.42M | +9.6% |
| 2020 | $128.16M | +1652.7% |
| 2019 | $7.31M | -27.5% |
| 2018 | $10.08M | +55.0% |
| 2017 | $6.51M | -67.1% |
| 2016 | $19.77M | -59.4% |
| 2015 | $48.70M | +483.3% |
| 2014 | $8.35M | -59.1% |
| 2013 | $20.39M | +840.1% |
| 2012 | $2.17M | +151.3% |
| 2011 | -$4.23M | +15.3% |
| 2010 | -$5.00M | -31.9% |
| 2009 | -$3.79M | +6.5% |
| 2008 | -$4.05M | -145.9% |
| 2007 | -$1.65M | -245.7% |
| 2007 | $1.13M | -67.5% |
| 2006 | $3.48M | +9.1% |
| 2005 | $3.19M | +302.2% |
| 2004 | -$1.58M | -32.0% |
| 2003 | -$1.20M | -66.1% |
| 2002 | -$719.4K | -199.3% |
| 2001 | -$240.4K | -982.4% |
| 2000 | $27.2K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.79M | -1.2% | -16.7% |
| June 30, 2025 | $58.61M | +11.9% | -17.3% |
| March 31, 2025 | $70.88M | +16.4% | -14.6% |
| December 31, 2024 | $82.95M | +18.9% | +67.9% |
| September 30, 2024 | $49.39M | -36.5% | -5.7% |
| June 30, 2024 | $52.39M | -39.5% | -14.0% |
| March 31, 2024 | $60.89M | -36.9% | -12.7% |
| December 31, 2023 | $69.74M | -34.4% | -10.4% |
- Cardiff Oncology, Inc. showed a decrease of -45.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2000–2025 period, Cardiff Oncology, Inc.’s stockholders equity has grown by 166522.6% (from $27.2 thousand to $45.39 million).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: